Physician profile
David Nazarian
NPI 1740461466
$984.00
in general payments reported to CMS, 2019-2025
12 companies · $28.17 in 2025
The $28.17 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2021: $256 · 2022: $38.80 · 2023: $165 · 2024: $82.14 · 2025: $28.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $320.97 | 2021-2023 | Signia |
| Johnson & Johnson Surgical Vision, INC. | $125.00 | 2019 | |
| Lilly USA, LLC | $122.37 | 2019 | |
| Glaukos Corporation | $112.70 | 2019 | |
| Intuitive Surgical, INC. | $100.00 | 2021 | |
| Indivior INC. | $53.85 | 2019 | |
| Revance Therapeutics, INC. | $32.56 | 2024 | |
| Abbvie INC. | $28.17 | 2025 | |
| Intra-Sana Laboratories | $26.98 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Novo Nordisk INC | $24.14 | 2022 | |
| Galderma Laboratories, L.P. | $22.60 | 2024 | |
| Currax Pharmaceuticals LLC | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nazarian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.